Dorsal Root Ganglion (DRG) Stimulation Portfolio

Proclaim DRG and lead product image

Portfolio Overview

  • A premier neurostimulation therapy for  focal chronic pain conditions1
  • A premium platform offering the patient‐centric advantages of Invisible Therapy
  • Delivers targeted stimulation for precise pain relief



THE CHOICE FOR BETTER OUTCOMES*

With DRG stimulation you can achieve superior outcomes and deliver precise relief for patients suffering from focal chronic intractable pain.1


The Science Behind the DRG

The dorsal root ganglion (DRG) plays a critical role in the development and maintenance of chronic pain.3,4 It contains cell bodies of primary sensory neurons that undergo pathophysiologic changes underlying in chronic pain.5,6 The DRG’s unique pain processes and its anatomical considerations make it an ideal interventional target to treat various focal chronic intractable pain conditions.

The DRG has emerged as an exciting target for the management of focal intractable chronic pain.


Superior Pain Relief for Focal Chronic Intractable Pain

Conventional tonic SCS has been successfully used since 1967 to manage chronic, intractable pain in the trunk and/or limbs.6 But for pain locations outside of or more focal than the trunk and/or limbs—as seen in chronic intractable pain conditions—conventional tonic SCS has been less successful or has resulted in extraneous stimulation.1

Today there is a better solution; stimulating the dorsal root ganglion (DRG) has been clinically proven to achieve pain relief in focal chronic intractable pain conditions of the lower limbs.1

Learn more about the Proclaim™ DRG neurostimulator system and Axium™ neurostimulator system.

See the Details

Infographic shows decrease in pain in patients who receive stimulation with DRG therapy
Physician writing on clipboard

ACCURATE Study: Proof That DRG Stimulation Works

The ACCURATE study is the largest randomized, controlled neuromodulation trial conducted in CRPS patients with lower limb pain to provide evidence of safety and efficacy in the United States. 

The data from the ACCURATE study suggests that DRG stimulation may offer a meaningful treatment aid for patients suffering from chronic pain conditions who are currently underserved by traditional SCS.

Read more about the study:
PDF ACCURATE Clinical Highlights (164 kb)

More Clinical Evidence


Proclaim™ DRG Neurostimulator System

Abbott offers the only systems that are FDA approved to stimulate the dorsal root ganglion (DRG), including the Proclaim™ DRG neurostimulator system.2 Combined with the patient-friendly advantages of Invisible Therapy™, the Proclaim™ DRG neurostimulator system helps to deliver precise relief and long-lasting therapy, so patients can focus on their lives instead of the pain.

See how our technology empowers you to achieve better outcomes* for treating patients with focal chronic intractable pain in the lower limbs due to CRPS with the Proclaim DRG neurostimulator system.

Proclaim™ DRG implantable pulse generator (IPG) neurostimulator system
Diagrammed drawing of the lumbar vertebrae (lower spinal cord)

Transforming the Treatment of Chronic Pain

At St. Jude Medical, our patient-focused approach to pain management is inspired by the care needs and challenges of patients with chronic pain. We offer the broadest range of therapies across the continuum of care to help physicians like you tailor your approach. Our investments in research, technology and partnerships can improve therapy outcomes and increase treatment options.

Partner with us to treat more patients with better results and transform the lives of more patients suffering from chronic pain.

Learn more about our approach to chronic pain

REFERENCES

*When compared to traditional spinal cord stimulation based on outcomes from the ACCURATE IDE study.
**Based on new technologies available for DRG therapy.
***As studied in the ACCURATE clinical trial.
†Based on 12 month data studied in the ACCURATE IDE Study.
1. Deer, TR, Levy, RM, Kramer, J, et al. (2017). Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 158(4): 669-681. http://dx.doi.org/10.1097/j.pain.0000000000000814 ACCURATE IDE STUDY, St. Jude Medical. (n=152)
2. Abbott. Data on File. SJM-PDRG-1017-0016
3. Pope, J. E., Deer, T. R., & Kramer, J. (2013). A systematic review: Current and future directions of dorsal root ganglion therapeutics to treat chronic pain. Pain Medicine, 14(10), 1477-1496. http://dx.doi.org/10.1111/pme.12171
4. Sapunar, D., Kostic, S., Banozic, A., & Puljak, L. (2012). Dorsal root ganglion—a potential new therapeutic target for neuropathic pain. Journal of Pain Research, 5, 31-38. http://dx.doi.org/10.2147/JPR.S26603
5. Devor, M. (1999). Unexplained peculiarities of the dorsal root ganglion. Pain, 82(Suppl. 1), S27-S35. http://dx.doi.org/10.1016/S0304-3959(99)00135-9
6. Chung, J. M., & Chung, K., (2002). Importance of hyperexcitability of DRG neurons in neuropathic pain. Pain Practice, 2(2), 87-97. http://dx.doi.org/10.1046/j.1533-2500.2002.02011.x

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.